HB0052 not checked
Huahai Pharmaceutical (Huaota)
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “An antibody- drug conjugate (ADC) that targets CD73 with SN38 as the payload”In the company’s words, NCT06992687 on ClinicalTrials.gov
- Tested for
- Solid Tumors
- Main trialPhase 1/2
- “To evaluate the safety and tolerability of HB0052 in patients with advanced solid tumors”In the company’s words, NCT06992687 on ClinicalTrials.gov
Other drugs for Solid Tumors
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Enrolling by invitation | 30 Sep 2025 | A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026